David H. Xiang on Muck Rack

David H. Xiang

As seen in: Wiley Online Library, MDPI, Scientific American, JAMA (The Journal of the American Medical Association), The Chronicle of Higher Education, The Harvard Crimson, NewsBreak, medRxiv, Physician's Weekly, 2 Minute Medicine and
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with David H.

Contact David H., search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

A dynamic microRNA profile that tracks a chemotherapy resistance phenotype in osteosarcoma. Implications for novel therapeutics.

|
By Andrew Kelly, David H. Xiang, Christopher E. Lietz, Erik T. Newman
| medRxiv
The authors have declared no competing interest. Supported by NIH R01 CA178908 Award to Dimitrios Spentzos, the Amy Chase McMahon Sarcoma Research Fund at the MGH Cancer Center, and the Casper Colson philanthropic donation to Dimitrios Spentzos and the Sarcoma Program at the MGH Cancer Center. The funding bodies had no role in the design of the study, and collection, analysis, and interpretation of the data, or in writing the manuscript.
Open in Who Shared View Duplicates (85) Issue with article?

Persistent Sweet syndrome post‐hematopoietic stem cell transplantation heralding molecular relapse of myelofibrosis

|
By David H. Xiang, Mohammadreza Pakyari, John Koreth, Connie R. Shi
| Wiley Online Library Verified
Corresponding Author Connie R. Shi Department of Dermatology, Brigham and Women's Hospital, Boston, Massachusetts, USA Center for Cutaneous Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, USA Correspondence Connie R. Shi, Dana Farber Cancer Institute, 450 Brookline Ave, Boston, MA 02215, USA. Email: cshi@bwh.harvard.edu Search for more papers by this author
Open in Who Shared Issue with article?

Weekly insulin icodec is more effective than daily basal insulin at reducing HbA1c

|
By David H. Xiang
| Physician's Weekly
1. In this randomized controlled trial, insulin icodec demonstrated superior HbA1c reduction as compared to once-daily basal insulin analogs in insulin-naïve type two diabetes (T2D). 2. Insulin icodec showed improved treatment satisfaction and compliance as compared to once-daily basal insulin analogs in insulin naïve T2D.
Open in Who Shared Issue with article?
See all 217 articles
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified